Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INO
STRONG SELLInovio Pharmaceuticals, Inc. · Healthcare · United States · $80M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines for infectious diseases, cancer, and other unmet medical needs using its proprietary CELLECTRA® delivery platform. The company utilizes a unique DNA plasmid technology and electroporation delivery system, aiming to generate robust and durable immune responses for therapeutic and prophylactic purposes. Inovio is a clinical-stage biopharmaceutical company with a broad pipeline, representing a speculative investment based on the success of its novel DNA medicine platform.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.3M | 0.8M | 0.2M | 65.3K | -81.5% | — | 0.7M | 51.3M | 2702.1% |
| EPS | -3.60 | -1.69 | -1.73 | -1.81 | — | -1.54 | -1.14 | -0.60 | — |
| Shares | 82.3M | 82.3M | 82.3M | 69.0M | -16.1% | 82.3M | — | — | — |
| Debt | 32.1M | 30.2M | 11.9M | 9.4M | -33.7% | 8.7M | — | — | — |
| Equity | 222.4M | 117.3M | 68.5M | 24.1M | -52.3% | — | — | — | — |
| Op CF | -216.2M | -124.4M | -104.1M | -88.6M | — | -83.3M | — | — | — |
| Inv CF | 109.6M | 87.4M | 104.1M | 14.0M | — | — | — | — | — |
| Fin CF | 81.8M | 5.0M | 51.5M | 53.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INO | Inovio Pharmaceuticals, Inc.(you) | $80M | 0 | STRONG SELL |
| EXOZ | eXoZymes, Inc. | $73M | 0 | STRONG SELL |
| ELTX | Elicio Therapeutics, Inc. | $79M | 3 | STRONG SELL |
| NTHI | NeOnc Technologies Holdings, Inc. | $89M | 1 | STRONG SELL |
| RNTX | Rein Therapeutics Inc. | $68M | 2 | STRONG SELL |
| 2257.HK | Sirnaomics Ltd. | $64M | 1 | STRONG SELL |
| CRDF | Cardiff Oncology, Inc. | $64M | 2 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $92M | 4 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $82M | 7 | STRONG SELL |
| 2592.HK | Cloudbreak Pharma Inc. | $110M | 1 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%